Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.

Virus-blocking compound Carragelose, out-licensed to major consumer health players such as Perrigo and Reckitt for use in OTC respiratory nasal sprays, is being adapted for use in the dry eye and allergy categories.

CRN adds education, events director; Mark Blumenthal award to David Winston; Heidebreicht heads Applied Nutrition in North America; Bucked Up Anime Line has character; and change at Bayer US pharma communications.

Exclusion from procurement processes, confiscation of revenues, and a fine of at least 4% of annual turnover are some of the penalties the European Parliament is considering for greenwashing as part of its position on the EU Green Claims Directive. 

Line extension for physician’s brand BrainMD intends to support secretion of glucagon-like peptide-1; research shows AllerPops prebiotic lozenges improved rhinitis allergy symptoms significantly; and Nutramax Laboratories developing Practitioner Formulas supplements with health care professionals.

Kenvue’s plans to drive sales include re-introducing brands to consumers and making “priority” of 15 brands, most in self care. “Overall, the execution of our recovery plan in the fourth quarter fell short of expectations,” says CEO Thibaut Mongon.

“So lacking in substance that it ‘stands out’ from the dozens of [patent infringement] challenges I have encountered as a judge in the last five years,” says Colm Connolly, Delaware district chief judge. His ruling doesn’t end the firms’ litigation as related cases continue in federal courts in California and New York.

“No” answers in New York federal court on whether all but two of Prevagen claims were “materially misleading” could put a fork in the road of a long dispute between FTC and supplement product manufacturers and marketers.

FTC Division of Marketing Practices assistant director concerned direct selling self-regulation group’s guidance “will encourage deceptive conduct and facilitate deceptive earnings claims.” DSA president says the concerns might reflect the thinking of agency’s staff more than the intent of the agency’s regulations.